title: Metabolism of benzo[a]pyrene in human bronchoalveolar H358 cells using liquid chromatography-mass spectrometry.
abstract: Benzo[ a]pyrene (B[ a]P), a representative polycyclic aromatic hydrocarbon (PAH), is metabolically activated by three enzymatic pathways: by peroxidases (e.g., cytochrome P450 peroxidase) to yield radical cations, by P4501A1/1B1 monooxygenation and epoxide hydrolase to yield diol epoxides, and by P4501A1/1B1 monooxygenation, epoxide hydrolase, and aldo-keto reductases (AKRs) to yield o-quinones. In humans, a major exposure site for environmental and tobacco smoke PAH is the lung; however, the profile of B[ a]P metabolites formed at this site has not been well characterized. In this study, human bronchoalveolar H358 cells were exposed to B[ a]P, and metabolites generated by peroxidase (B[ a]P-1,6- and B[ a]P-3,6-diones), from cytochrome P4501A1/1B1 monooxygenation [3-hydroxy-B[ a]P, B[ a]P-7,8- and 9,10- trans-dihydrodiols, and B[ a]P- r-7, t-8, t-9, c-10-tetrahydrotetrol (B[ a]P-tetraol-1)], and from AKRs (B[ a]P-7,8-dione) were detected and quantified by RP-HPLC, with in-line photo-diode array and radiometric detection, and identified by liquid chromatography-mass spectrometry (LC-MS). Progress curves showed a lag phase in the formation of 3-hydroxy-B[ a]P, B[ a]P-7,8- trans-dihydrodiol, B[ a]P-tetraol-1, and B[ a]P-7,8-dione over 24 h. Northern blot analysis showed that B[ a]P induced P4501B1 and AKR1C isoforms in H358 cells in a time-dependent manner, providing an explanation for the lag phase. Pretreatment of H358 cells with 10 nM 2,3,7,8-tetrachlorodibenzo- p-dioxin (TCDD) eliminated this lag phase but did not alter the levels of the individual metabolites observed, suggesting that both B[ a]P and TCDD induction ultimately yield the same B[ a]P metabolic profile. The one exception was B[ a]P-3,6-dione which was formed without a lag phase in the absence and presence of TCDD, suggesting that the peroxidase responsible for its formation was neither P4501A1 nor 1B1. Candidate peroxidases that remain include PGH synthases and uninduced P450 isoforms. This study shows that the P4501A1/1B1 and AKR pathways are inducible in human lung cells and that the peroxidase pathway was not. It also provides evidence that each of the pathways of PAH activation yields their distinctive metabolites in H358 human lung cells and that each pathway may contribute to the carcinogenic process.
authors: Centers of Excellence in Environmental Toxicology and Cancer Pharmacology, Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6084, USA.
authors: Hao
authors: H
authors: Jiang
authors: Stacy L
authors: SL
authors: Gelhaus
authors: Dipti
authors: D
authors: Mangal
authors: Ronald G
authors: RG
authors: Harvey
authors: Ian A
authors: IA
authors: Blair
authors: Trevor M
authors: TM
authors: Penning
mesh_terms: D015089:20-Hydroxysteroid Dehydrogenases / Q000378:metabolism; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism; D001564:Benzo(a)pyrene / Q000737:chemistry / Q000378:metabolism* / Q000633:toxicity; D045744:Cell Line, Tumor; D002853:Chromatography, Liquid; D065633:Cytochrome P-450 CYP1B1; D006801:Humans; D013058:Mass Spectrometry; D015394:Molecular Structure; D010544:Peroxidases / Q000378:metabolism; D011650:Pulmonary Alveoli / Q000187:drug effects* / Q000378:metabolism*
chemical_list: D001564:Benzo(a)pyrene; D015089:20-Hydroxysteroid Dehydrogenases; C115140:3 alpha-beta, 20 beta-hydroxysteroid dehydrogenase; D010544:Peroxidases; D001189:Aryl Hydrocarbon Hydroxylases; C585496:CYP1B1 protein, human; D065633:Cytochrome P-450 CYP1B1
references: Cancer Res. 1975 Dec;35(12):3651-5
references: 1192426
references: Chem Biol Interact. 1996 Jan 5;99(1-3):55-72
references: 8620579
references: Cancer Res. 1996 Jul 1;56(13):2979-84
references: 8674051
references: Drug Metab Dispos. 1996 May;24(5):515-22
references: 8723730
references: Chem Res Toxicol. 1996 Jan-Feb;9(1):84-92
references: 8924621
references: Science. 1996 Oct 18;274(5286):430-2
references: 8832894
references: Chem Res Toxicol. 1996 Oct-Nov;9(7):1113-6
references: 8902265
references: Hum Exp Toxicol. 1997 Oct;16(10):589-95
references: 9363476
references: Biochemistry. 1998 May 12;37(19):6781-90
references: 9578563
references: Chem Res Toxicol. 1999 Jan;12(1):1-18
references: 9894013
references: Cancer Res. 1999 Feb 1;59(3):607-14
references: 9973208
references: Chem Res Toxicol. 1999 Mar;12(3):237-46
references: 10077486
references: Chem Res Toxicol. 1999 Jul;12(7):623-9
references: 10409402
references: J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210
references: 10413421
references: Chem Res Toxicol. 2005 Jun;18(6):1026-37
references: 15962938
references: Exp Toxicol Pathol. 2005 Jul;57 Suppl 1:189-204
references: 16092727
references: Lancet Oncol. 2005 Dec;6(12):931-2
references: 16353404
references: Chem Res Toxicol. 2006 Jan;19(1):68-78
references: 16411658
references: Toxicol Lett. 2006 Apr 10;162(2-3):181-5
references: 16406420
references: Mol Pharmacol. 2006 May;69(5):1662-72
references: 16478829
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 19;836(1-2):92-7
references: 16617038
references: Anal Biochem. 2006 Aug 15;355(2):213-23
references: 16797471
references: Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):187-202
references: 16922636
references: Chem Res Toxicol. 2006 Nov;19(11):1441-50
references: 17112231
references: Am J Respir Cell Mol Biol. 2000 Mar;22(3):360-6
references: 10696073
references: Chem Res Toxicol. 2000 Apr;13(4):271-80
references: 10775327
references: Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):373-80
references: 10794481
references: Cancer Res. 2001 Mar 15;61(6):2727-31
references: 11289154
references: Biochemistry. 2001 Sep 11;40(36):10901-10
references: 11535067
references: Chem Res Toxicol. 2002 Jun;15(6):832-42
references: 12067251
references: J Biol Chem. 2002 Jul 5;277(27):24799-808
references: 11978787
references: Crit Rev Toxicol. 2002 Sep;32(5):391-411
references: 12389869
references: J Toxicol Environ Health A. 2003 Jul 11;66(13):1189-205
references: 12851118
references: Cancer Res. 2003 Nov 15;63(22):7825-33
references: 14633709
references: J Org Chem. 2004 Mar 19;69(6):2024-32
references: 15058949
references: Chem Res Toxicol. 2004 Jun;17(6):827-38
references: 15206904
references: Chem Res Toxicol. 2007 Mar;20(3):424-31
references: 17295519
references: Biochemistry. 1977 Apr 5;16(7):1467-73
references: 191070
references: Mutat Res. 1977 Sep;44(3):313-26
references: 333280
references: Science. 1978 Feb 17;199(4330):778-81
references: 622566
references: Physiol Rev. 1980 Oct;60(4):1107-66
references: 7001511
references: Cancer Res. 1982 Dec;42(12):4875-917
references: 6814745
references: IARC Monogr Eval Carcinog Risk Chem Hum. 1983 Dec;32:1-453
references: 6586639
references: Nature. 1984 Aug 16-22;310(5978):586-9
references: 6431299
references: Cancer Lett. 1985 Nov;29(2):139-50
references: 4075284
references: IARC Monogr Eval Carcinog Risk Chem Hum. 1985 Sep;37:1-268
references: 3866741
references: Cancer Res. 1986 Sep;46(9):4368-71
references: 3731094
references: Carcinogenesis. 1987 Jul;8(7):983-8
references: 3594730
references: J Biol Chem. 1988 Nov 25;263(33):17221-4
references: 2846558
references: Cancer Res. 1989 Nov 15;49(22):6304-12
references: 2509067
references: Chem Res Toxicol. 1992 Mar-Apr;5(2):302-9
references: 1643262
references: Carcinogenesis. 1993 Mar;14(3):475-82
references: 8384091
references: Biochem Biophys Res Commun. 1993 May 14;192(3):1373-9
references: 8507205
references: J Biol Chem. 1994 May 6;269(18):13092-9
references: 8175734
references: Xenobiotica. 1995 Jul;25(7):677-88
references: 7483666
references: Toxicology. 1995 Dec 28;105(2-3):403-13
references: 8571376
references: Biochemistry. 1977 Mar 8;16(5):932-8
references: 843522